March 19, 2018 1:53 AM ET


Company Overview of 3-V Biosciences, Inc.

Company Overview

3-V Biosciences, Inc. operates as a biopharmaceutical company that discovers and develops therapeutics for the treatment of oncology and infectious diseases. The company offers a TVB-2640, a fatty acid synthase inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. It also focuses on developing antiviral therapeutic candidates for respiratory syncytial virus, cytomegalovirus, and other human pathogens. The company was incorporated in 2006 and is based in Menlo Park, California.

1050 Hamilton Court

Menlo Park, CA 94025

United States

Founded in 2006



Key Executives for 3-V Biosciences, Inc.

Chief Executive Officer, President and Director
Executive Chairman
Age: 51
Chief Financial Officer and Senior Vice President of Business & Financial Operations
Compensation as of Fiscal Year 2017.

3-V Biosciences, Inc. Key Developments

3-V Biosciences, Inc. to Present Clinical Data Demonstrating TVB-2640 Inhibits Fatty Acid Synthesis

3-V Biosciences, Inc. announced that it will present data on its first-in-class fatty acid synthase (FASN) inhibitors at the upcoming AASLD meeting. Poster #1972 "Pharmacologic inhibition of FASN reverses diet-induced steatohepatitis in mice and inhibits lipogenesis in humans" presents data from a Phase 1 clinical-pharmacology study conducted in collaboration with leading experts in the field, Drs. Elizabeth Parks and Camila Manrique at the University of Missouri, Columbia School of Medicine. This study shows that 3-V Biosciences' lead drug, TVB-2640, directly inhibits hepatic lipogenesis, a driver of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), in healthy males who have characteristics of metabolic syndrome (i.e. BMI >26). A second poster #1994 "Fatty acid synthase inhibitor TVB-3664 reduces collagen accumulation in bleomycin-induced murine skin fibrosis and reverses multiple components of diet-induced and biopsy-confirmed nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone" was recognized as a Presidential Poster of Distinction. These studies describe the therapeutic potential of FASN inhibitors in mouse models of NASH and their ability to decrease expression of genes associated with fibrosis in human liver stellate cells.

3-V Biosciences to Present Data At the AACR 2017 Annual Meeting in Washington, DC

3-V Biosciences, Inc. announced that it will present data from its ongoing Phase 1 clinical study of TVB-2640 in solid tumor patients at the AACR annual meeting in Washington, D.C. The abstract "First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640" has been selected for an oral presentation as part of a mini-symposium session titled "Novel Agent and Intervention Clinical Trials" on April 4, 2017 at 4:05PM local time. The Principal Investigator presenting details about the trial is Dr. Gerald Falchook from the Sarah Cannon Research Institute at HealthONE, Denver, CO.

3-V Biosciences, Inc. Presents at 2016 BIO Investor Forum, Oct-19-2016 03:00 PM

3-V Biosciences, Inc. Presents at 2016 BIO Investor Forum, Oct-19-2016 03:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 3-V Biosciences, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at